Identifying predictors of neuropathic pain medication prescribing, adherence, and discontinuation: a systematic review and meta-analysis
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Pharmacoepidemiological studies show that large proportions of people with neuropathic pain (NP) are not prescribed the medications recommended for NP, do not adhere well to these medications, and/or often discontinue the treatment within half a year. Identifying what predicts these outcomes can inform a strategy to ensure that people with NP are prescribed recommended medication and continue their treatment when appropriate.
Methods
We carried out a systematic review and meta-analysis to identify predictors of pain medication prescribing, adherence, and discontinuation in adults with NP (PROSPERO ID: CRD42023464307). Electronic searches were conducted in Embase, PubMed, Web of Science, and CINAHL Plus.
Results
We identified 60 relevant studies and divided them into non-mutually exclusive categories based on the outcomes they had investigated. There were 45 studies on prescribing, 14 on adherence, and 25 on discontinuation. Predictors associated with being prescribed recommended NP medications as the first choice included white ethnicity, having diabetes, and/or having a mental health disorder. Predictors associated with better adherence included being prescribed serotonin-norepinephrine reuptake inhibitors compared to gabapentinoids or tricyclic antidepressants; dose titration, and/or implementing a medicine reminder. Predictors associated with a higher likelihood of discontinuation included being prescribed medications other than second-generation antidepressants and/or having a combination of NP medications rather than a single medication.
Conclusions
Thus, there is a need to focus on improving NP medication prescribing for ethnic minorities and people with non-diabetic NP. Adherence and persistence with NP medications could be improved by prioritising the prescribing of serotonin-norepinephrine reuptake inhibitors if indicated.
